On October 20, 2021 Point32Health and Takeda Pharmaceuticals America, Inc. reported that they have signed an innovative risk-sharing agreement around Takeda’s ALUNBRIG (brigatinib), a potent and selective tyrosine kinase inhibitor (TKI) that is approved for adult patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test (Press release, Takeda, OCT 20, 2021, View Source [SID1234594767]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The agreement will make ALUNBRIG broadly available to Point32Health’s more than two million members – with Takeda standing behind the medicine with a unique outcomes-based structure. The agreement is among the first risk-sharing contracts in oncology and the very first in ALK+NSCLC.
"Given the importance of facilitating cutting-edge oncology treatment and also the reality that not all patients show a positive response, reimbursement for oncology treatments is an area that is prime for innovative financing approaches," said Michael Sherman, MD, chief medical officer and executive vice president, Point32Health. "We’re excited to be able to demonstrate the value of ALUNBRIG as a treatment option for people with ALK+ NSCLC. Collaborating with Takeda to share risk makes this agreement a crucial milestone in bringing cost-effectiveness to cancer care."
"Takeda is committed to identifying and collaborating with payers on innovative and bold solutions that help ensure patients have access to our transformative therapeutics," said Dion Warren, vice president, head, U.S. Business Unit, Takeda Oncology. "Through this collaboration, Point32Health is able to allow broader access to ALUNBRIG because Takeda stands behind the value of its medicine and is willing to minimize the financial risk."